key: cord-0859237-zfvm1rqq
authors: Pegat, Antoine; Vogrig, Alberto; Khouri, Charles; Masmoudi, Kamel; Vial, Thierry; Bernard, Emilien
title: Adenovirus COVID‐19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis
date: 2021-11-12
journal: Ann Neurol
DOI: 10.1002/ana.26258
sha: d5314743c026e7a341a1d8d27fe43c5a0ba989ab
doc_id: 859237
cord_uid: zfvm1rqq

nan

Johnson), and 2 of 24 (8.3%) who received other vaccines. FP-GBS was significantly more frequent after adenovirus-vectored vaccines (χ 2 : p = 6.44 Â 10 À8 ; Fig) .

We then extracted all cases reported in the French pharmacovigilance database (June 29, 2021), which is more detailed and more up to date than the VigiBase. Among the 48,907 cases reported with COVID-19 vaccines, there were 69 (0.1%) cases of GBS, of which 23 involved FP (33.3%). This These results indicate that cases of GBS occurring after administration of adenovirus-vectored vaccines present a specific phenotype, which supports a causal relationship between such exposure and this syndrome. Although it is likely that underreporting of FP exists in these databases, there is no reason for differential reporting of FP-GBS between vaccines. Future prospective studies are needed to elucidate the specific immunopathological mechanism underlying this possible complication.

Guillain-Barre syndrome following CHADOX1-S/NCOV -19 vaccine

Guillain-Barre syndrome variant occurring after SARS-COV-2 vaccination

Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine

Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

Guillain-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality

We thank VigiBase and the French network of pharmacovigilance centers for giving us access to the data. The data supplied to VigiBase come from a variety of sources, and the likelihood of a causal relationship is not the same in all reports. The information does not represent the opinions of the Uppsala Monitoring Centre or the World Health Organization. We thank Philip Robinson (DRS, Lyon Civil Hospices) for help in manuscript preparation.

A.P., A.V., and E.B. contributed to the conception and design of the study. All authors contributed to the acquisition and analysis of data. A.P. and A.V. contributed to drafting the manuscript. A.P. contributed to drafting the figure.